Allergy Drugs (MCP-6165) - Global Industry Analysts, Inc.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

3

$100

Study Reliability and Reporting Limitations.....I-1

Disclaimers.....I-2

Data Interpretation & Reporting Level.....I-3

Quantitative Techniques & Analytics.....I-3

Product Definitions and Scope of Study.....I-3

II. A US MARKET REPORT

29

$2250

1. MARKET REVIEW.....II-1

6

$1000

Allergy – A Global Perspective.....II-1

Allergy Prevalence.....II-1

Allergy - A US Perspective.....II-1

Allergy Prevalence.....II-1

1

$105

Market Overview.....II-2

Market Outlook.....II-2

Manufacturers Leverage Opportunity, Announce New Product Launches.....II-2

1

$105

Zyrtec’ Move to OTC Aisles Perks Up OTC Sales.....II-3

Allergy Patients Turn to Complimentary Medicine.....II-3

1

$105

Leading Allergy Products.....II-4

Table 1: US Allergy Drugs Market - Percentage Share Breakdown of Antihistamine Products by New Prescriptions for 2007, 2008 and 2009 (includes corresponding Graph/Chart).....II-4

1

$300

Table 2: US Allergy Drugs Market - Percentage Share Breakdown of Antihistamine + Decongestant Combination Products by New Prescription for 2007, 2008 and 2009 (includes corresponding Graph/Chart).....II-5

Table 3: US Allergy Drugs Market - Percentage Share Breakdown of Allergy Nasal Spray Products by Total Prescriptions (in thousands) for 2007 and 2008 (includes corresponding Graph/Chart).....II-5

1

$300

Table 4: US Allergy Drugs Market - Percentage Share Breakdown of Allergy Nasal Spray Products by Value Sales for 2007 and 2008 (includes corresponding Graph/Chart).....II-6

1

$300

2. ALLERGY OVERVIEW.....II-7

9

$745

Allergy: Definition.....II-7

Causes/ Factors.....II-7

Symptoms/ Triggers.....II-7

1

$105

Allergic Rhinitis – A Common Allergy.....II-8

Types of Allergic Rhinitis.....II-8

Diagnosis of Allergic Rhinitis.....II-8

1

$105

Treatment of Allergy.....II-9

Antihistamines.....II-9

1

$105

Antihistamines - List of Select Generic Formulations and Products.....II-10

Risks/ Side Effects.....II-10

Decongestants.....II-10

1

$105

Decongestants – List of Select Generic Formulations and Products.....II-11

Decongestant + Antihistamine - List of Select Generic Formulations and

Products.....II-11

Risks/ Side Effects.....II-11

Corticosteroids.....II-11

1

$105

Intranasal Corticosteroids – List of Select Generic Formulations and

Products.....II-12

Side Effects.....II-12

Allergy Shots.....II-12

1

$105

Other Medicines.....II-13

Sodium Cromoglycate.....II-13

Cromolyn Sodium.....II-13

Leukotriene Modifiers.....II-13

Glucocorticoids.....II-13

Leading Allergy Drugs.....II-13

Claritin.....II-13

1

$105

Zyrtec.....II-14

Benadryl.....II-14

Pollinex® Quattro.....II-14

Cortaid.....II-14

Visine-A.....II-14

1

$105

Ocean Sinus Irrigation.....II-15

Crolom Eye Drops.....II-15

1

$105

3. PRODUCT INTRODUCTIONS/ APPROVALS.....II-16

5

$450

McNeil Consumer Healthcare Launches Zyrtec for Children.....II-16

Cobalis Announces Online Launch of Anti-allergy Product.....II-16

Collegium Pharmaceutical Obtains FDA Approval for AllerNaze.....II-16

1

$105

Sanofi-aventis and UCB Win NDA Approval for Xyzal Oral Solution.....II-17

Sepracor Launches Omnaris Nasal Spray for Seasonal and Perennial Allergies.....II-17

1

$105

Sanofi Aventis Launches Allegra Orally Disintegrating Tablets.....II-18

Ranbaxy Wins FDA Approval for Generic Zyrtec.....II-18

Wockhardt Introduces Generic Cetirizine Tablets.....II-18

Hi-Tech Pharmacal Receives FDA Approval for Fluticasone Propionate.....II-18

1

$105

Boca Pharmacal Wins FDA Approval for Palgic’s Generic Product.....II-19

Ranbaxy Receives FDA Approval for Cetirizine Hydrochloride Oral Solution.....II-19

Perrigo and Teva Receive FDA Approval for Zyrtec-D.....II-19

Sanofi-aventis Receives FDA Approval for Nasacort AQ® Nasal Spray.....II-19

Sanofi-aventis and UCB Introduce Xyzal Anti-allergy Medication.....II-19

1

$105

Sanofi-aventis Wins FDA Approval for Allegra® Oral Suspension.....II-20

Matrixx Launches Zicam Multi-Symptom Cold & Flu Relief Products.....II-20

Ranbaxy Receives Approval to Market Claritin Reditabs’ Generic.....II-20

Procter & Gamble Introduces Nyquil D.....II-20

Leiner to Launch Naproxen Cold & Sinus Private Label Allergy Products.....II-20

1

$105

4. RECENT INDUSTRY ACTIVITY.....II-21

4

$420

Merck Announces Business Merger Plan with Schering-Plough.....II-21

Hi-Tech Pharmacal to Acquire ECR Pharmaceuticals.....II-21

IBT Laboratories and ViraCor Announce Merger Plan.....II-21

1

$105

Lupin Acquires Rights to Collegium’s Intra-nasal Steroid.....II-22

Cobalis and Melodic Sign Agreement for PreHistin.....II-22

Patheon Receives Contract to Commercialize Allergy Drugs.....II-22

1

$105

Boehringer Ingelheim Signs Agreement for Actimis Acquisition.....II-23

Perrigo Acquires US Rights to Levocetirizine Tablets.....II-23

Sciele Pharma Acquires Verus Pharmaceuticals’ Allergy Injection.....II-23

1

$105

Sanofi-Aventis and Johns Hopkins University Division Sign Agreement.....II-24

Pipex Announces Effective Pharmaceuticals Acquisition.....II-24

Meda to Take Over American Company, MedPointe.....II-24

Private Group Proposes to Acquire Majority Interest in Inyx.....II-24

1

$105

5. FOCUS ON SELECT PLAYERS.....II-25

3

$315

Collegium Pharmaceutical, Inc......II-25

McNeil Consumer Healthcare.....II-25

Meda Pharmaceuticals, Inc......II-25

Novartis Consumer Healthcare, Inc......II-25

1

$105

Schering-Plough Corp......II-26

Sepracor, Inc......II-26

1

$105

Vicks.....II-27

1

$105

6. US MARKET PERSPECTIVE.....II-28

Table 5: US Recent Past, Current & Future Analysis for Allergy Drugs by Product Segment – Prescription Antihistamines, Prescription Corticosteroids and OTC Allergy Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart).....II-28

Table 6: US Historic Review for Allergy Drugs by Product Segment – Prescription Antihistamines, Prescription Corticosteroid and OTC Allergy Drugs Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2001 through 2006 (includes corresponding Graph/Chart).....II-28

1

$300

Table 7: US 15-Year Perspective for Allergy Drugs by Product Segment – Percentage Breakdown of Annual Value Sales for Prescription Antihistamines, Prescription Corticosteroids and OTC Allergy Drugs Markets for Years 2003, 2009 & 2015 (includes corresponding Graph/Chart).....II-29

1

$300

III. REST OF WORLD MARKETS

10

$900

1. CANADA.....III-1

2

$210

Allergy – Overview.....III-1

Strategic Corporate Developments.....III-1

2

$210

2. JAPAN.....III-3

1

$105

Allergy – Overview.....III-3

Product Approvals.....III-3

1

$105

3. EUROPE.....III-4

4

$420

Allergy - Prevalence.....III-4

United Kingdom.....III-4

Allergy – Overview.....III-4

Russia.....III-4

Allergy – Overview.....III-4

Product Launch.....III-4

1

$105

Strategic Corporate Developments.....III-5

Select Players.....III-5

3

$315

4. ASIA-PACIFIC.....III-8

3

$315

Allergy – Overview.....III-8

Australia and New Zealand.....III-8

China.....III-8

Market Overview.....III-8

1

$105

OTC Medications – A Small, But Growing Market.....III-9

Market Analytics.....III-9

Table 8: Chinese Recent Past, Current & Future Analysis for Allergy Drugs – Annual Sales Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart).....III-9

1

$200

India.....III-10

Market Overview.....III-10

Malaysia.....III-10

Allergy – Overview.....III-10

1

$105

IV. COMPETITIVE LANDSCAPE

527

$995

Total Companies Profiled: 109 (including Divisions/Subsidiaries - 139)
Region/Country                 Players

The United States                  26   
Canada                              2
Japan                               8
Europe                             40
     France                         4
     Germany                        7
     The United Kingdom             4
     Italy                          4
     Spain                          4
     Rest of Europe                17
Asia-Pacific (Excluding Japan)     49
Middle-east                        13      
Africa                              1

Click here to request a full table of contents and more details on this project.

ALLERGY DRUGS - A US MARKET REPORT

Research Abstract

Complimentary Market Brief:

TABLE OF CONTENTS

ALLERGY DRUGS - A US MARKET REPORT stLight.options({ publisher:'12345' });

Research Abstract

Complimentary Market Brief:

TABLE OF CONTENTS

ALLERGY DRUGS - A US MARKET REPORT